On May 1, 2024, mdxhealth closed a $100 million loan and security agreement with funds managed by OrbiMed Advisors. The Company drew down $55 million from this loan, replacing its existing $35 million debt funded by an affiliate of Innovatus Capital Partners, LLC. At the option of the Company, an additional $45 million can be drawn under the OrbiMed facility, consisting of a $25 million delayed draw term loan and a $20 million delayed draw term loan, in 2025 and 2026 respectively, subject to certain conditions. The loans are secured by substantially all assets of the Company, including intellectual property rights. Remaining proceeds of the loans will be used for working capital purposes and to fund general business requirements.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXH:
- These 2 ‘Strong Buy’ Penny Stocks Could Go Boom, Say Analysts
- Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering
- MDxHealth price target raised to $7 from $6 at Piper Sandler
- MDxHealth price target raised to $8 from $7 at BTIG
- MDxHealth sees 1H adjusted EBITDA profitability in 2025